Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Software Development

14 Feb 2008 07:01

Angle PLC14 February 2008 For Immediate Release 14 February 2008 ANGLE plc Software Development Kit Launched by Geomerics ANGLE plc is pleased to announce that its venture company Geomerics hascompleted its Software Development Kit (SDK) for Enlighten, the revolutionaryradiosity lighting engine for PLAYSTATION(R)3, the Xbox 360(TM) entertainmentsystem from Microsoft and PC. Enlighten's SDK comprises a modular toolkit withan emphasis on easy integration into existing development frameworks. It alsoboasts intuitive operation designed with artists in mind and full support forindustry standard packages such as 3D Studio Max and Maya for maximumoperability. Enlighten's radiosity solution represents a generational step in videogamegraphics technology, surpassing all currently popular lighting techniques.Radiosity is the ability to model light as it bounces from surfaces and it iskey to generating high quality visual images. Current technologies forgenerating radiosity lighting involve either pre-computing it in advance, orfaking it with multiple hidden lights. These methods are typically inflexible,time-consuming and often generate poor results. Enlighten computes full multiple-bounce radiosity at runtime, giving developersthe quality of pre-computed lighting without the pre-compute. In-game lightingcan also be fully dynamic, giving designers a powerful new tool with hugepotential for enhancing the atmosphere and mood of any scene. Additionally,Enlighten's instantaneous feedback means that artists are freed up to experimentwith light, shadow and colour in dramatic new ways - just as if they were usingreal lights on a studio set. Gary Lewis, CEO, Geomerics comments: "We are delighted to be announcing the launch of the Enlighten SDK. With our SDKcompleted, we are looking forward to seeing Enlighten gaining the support itdeserves within the games industry. We are certain that once developers gettheir hands on the SDK and experiment with it for themselves, they will see thetrue power and versatility of Enlighten and the huge potential it has forrevolutionising the look of videogames for years to come." Geomerics will be at Expo Suite 561 throughout GDC Expo 2008, which runs from20th to the 22nd February. To book a meeting please contact: info@geomerics.com Enlighten is available for licensing for PC, Xbox 360 and Playstation 3. Formore information please contact: sales@geomerics.com Enquiries: ANGLE plc 01483 295830Andrew Newland, Chief ExecutiveIan Griffiths, Finance Director Buchanan Communications 0207 466 5000Richard Darby, Suzanne Brocks, James Strong Notes to Editors Angle plc Founded in 1994, ANGLE is an international venture management company focusingon the commercialisation of technology and the development of technology-basedindustry. ANGLE creates, develops and advises technology businesses on its ownbehalf and for its clients. ANGLE has a 48% equity holding in Geomerics Ltd.ANGLE is listed on AIM (AGL.L); further information can be found onwww.ANGLEplc.com Geomerics Ltd Geomerics is an innovation-led company specialising in graphics software for thegames industry and beyond. It is built on a combination of advanced in-house IP,a remarkable research team, and strong management experience. The company'sfirst product is Enlighten. Enlighten radically transforms the way that lightingis handled in computer games. Instead of pre-baking the effects of globalillumination into the scene they can now be computed at run time, allowing forfully dynamic lighting. This dramatically enhances realism as well as opening upa new world of creative possibilities for designers and artists. Further information can be found on www.geomerics.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th Dec 20237:00 amRNSANGLE launches Portrait+ CTC kit at SABCS
9th Nov 20237:00 amRNSLaunch of PD-L1 test to support cancer studies
9th Nov 20237:00 amRNSTrading and business update
25th Oct 20237:00 amRNSSupporting characterisation of CTCs in HNSCC
3rd Oct 20237:00 amRNSParsortix outperforms standard for DTC harvest
29th Sep 20237:00 amRNSParsortix system showcased at ACTC conference
7th Sep 20237:00 amRNSInterim Results for the period ended 30 June 2023
4th Sep 20237:00 amRNSANGLE launch of Portrait Flex assay
15th Aug 20237:00 amRNSANGLE notice of interim results
28th Jun 20234:54 pmRNSResult of 2023 Annual General Meeting
27th Jun 202312:24 pmRNSStandard form for notification of major holdings
5th Jun 20237:00 amRNSANGLE announces senior management appointments
25th May 20237:00 amRNSPharma services contract with Artios Pharma
22nd May 20237:00 amRNSBoard change - appointment of new Chairman
21st Apr 202312:04 pmRNSANGLE presentation via Investor Meet Company
21st Apr 20237:00 amRNSResults for the year ended 31 December 2022
19th Apr 20237:00 amRNSANGLE announces partnership with BioView
17th Apr 20237:00 amRNSANGLE Parsortix poster presented at AACR 2023
13th Apr 20237:00 amRNSPharma Services Contract with Crescendo Biologics
3rd Apr 20237:00 amRNSNotice of Preliminary Results and Webcast
10th Mar 20237:00 amRNSIssue of LTIP Options and Share Options
9th Mar 20233:03 pmRNSHolding(s) in Company
9th Feb 20232:44 pmRNSDirector/PDMR shareholding
19th Jan 20237:00 amRNSAppointment of Non-Executive Director
11th Jan 20235:20 pmRNSHolding(s) in Company
10th Jan 20236:20 pmRNSHolding(s) in Company
6th Jan 202311:05 amRNSSecond Price Monitoring Extn
6th Jan 202311:00 amRNSPrice Monitoring Extension
5th Jan 20239:05 amRNSSecond Price Monitoring Extn
5th Jan 20239:00 amRNSPrice Monitoring Extension
5th Jan 20237:01 amRNSAppointment of Non-Executive Director
5th Jan 20237:00 amRNSBusiness Update
12th Dec 20227:00 amRNSTwo Parsortix posters presented at SABCS
2nd Dec 20225:30 pmRNSIssue of Equity
2nd Nov 20227:00 amRNSMultiple downstream analysis techniques for CTCs
1st Nov 20224:41 pmRNSSecond Price Monitoring Extn
1st Nov 20224:35 pmRNSPrice Monitoring Extension
24th Oct 20227:00 amRNSParsortix poster presented at ISLB meeting
21st Oct 20226:15 pmRNSIssue of Equity
18th Oct 20227:00 amRNSStreamlining of operations to increase cash runway
17th Oct 20222:23 pmRNSTR-1: Notification of major holdings
12th Oct 20227:00 amRNSFirst regional distribution agreement
30th Sep 20225:30 pmRNSHolding(s) in Company
30th Sep 20225:30 pmRNSIssue of Equity
29th Sep 20227:00 amRNSInterim Results
29th Sep 20227:00 amRNSPositive headline results from ovarian study
28th Sep 20227:00 amRNSStudy using Parsortix in head and neck cancer
13th Sep 20227:00 amRNSNew poster presented at ASCP Meeting
12th Sep 20227:30 amRNSNovel assay predicts malignancy in pelvic mass
1st Sep 20227:00 amRNSNotice of Interim Results and Webcast

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.